EX-10.25 8 v429366_ex10-25.htm EXHIBIT 10.25
Exhibit 10.25
***Text Omitted and Filed Separately
With Securities and Exchange Commission
Confidential Treatment Requested
Under 17 C.F.R. Section 200.80(b)(4)
and 240.24b-2
DATED 4th November 2015 (“Agreement Date”)
| (1) | AmpliPhi Bioscience Corporation |
| (2) | The University of Leicester |
COLLABORATION Agreement
COLLABORATION Agreement
(the ‘Agreement’)
BETWEEN:
| (1) | AmpliPhi Biosciences Corporation, having offices at 3579 Valley Centre Drive, Suite 100, San Diego, CA 92130 (“APHB”) (the ‘Sponsor’); and |
| (2) | The University of Leicester of University Road, Leicester LE1 7RH, United Kingdom (‘Leicester’). |
Each a ‘Party’ and together the ‘Parties’.
INTRODUCTION
| (A) | Leicester through its employee Prof Martha Clokie has materials and know-how for use in the study of bacteriophages specific for C. difficile. |
| (B) | AmpliPhi wish to develop a phage therapeutic to resolve C. difficile infections and are funding Leicester to carry out development work. |
AGREED
| 1 | Interpretation and Defined Terms in this Agreement |
In this Agreement, the terms set out below will have the following meanings:-
| 1.1 | ‘Arising IP’ means all (or any part) of the IP written, originated, conceived or made in the conduct of the Project by, or on behalf of, or jointly with Leicester. |
| 1.2 | ‘Background IP’ means:- |
| 1.2.1 | any IP owned by either Party at the start of the Project; and |
| 1.2.2 | any specific IP necessary to the Project which the owning Party agrees in writing to make available. |
| 1.3 | ‘Confidential Information’ means any commercial, technical and other information and data (of whatever nature and form) proprietary to the Party disclosing it (the ‘Disclosing Party’) which is directly or indirectly disclosed or made available by or on behalf of the Disclosing Party to the other Party (the ‘Receiving Party’), whether in writing, orally, in drawings, by site visits, by access to computer software or data or in any other manner. |
| 1.4 | ‘Contract Period’ means from 13th November 2015 until 12th November 2018. |
| 1.5 | ‘Costs’ means the contribution of the Sponsor to the costs of the Project as set out in Annex 2. |
| 1.6 | ‘Intellectual Property’ and ‘IP’ means all patents, registered designs, trademarks and service marks (whether registered or not), copyright, database rights, plant breeders rights, design right, know-how, information and all similar property including that subsisting (in any part of the world) in inventions, designs, performances, computer programs, semiconductor topographies, confidential information, business names, goodwill and the styles of presentation of goods or services and in applications for protection of them in any jurisdiction. |
| 1.7 | ‘Licence Agreement’ means the licence agreement between Leicester and the Sponsor dated 17th September 2013. |
| 1.8 | ‘Principal Investigator’ means Professor Martha Clokie (or such other employee or employees of Leicester as the Parties reasonably agree). |
| 1.9 | ‘Project’ means the project as described in Annex 1 under the direction of the Principal Investigator. |
| 1.10 | ‘Results’ means any results generated by or on behalf of a Party under the Project including materials, data and information and other outputs in any format. |
| 1.11 | References to ‘including’ in this Agreement in the context of a list or description of items shall be construed as meaning ‘including without limiting the generality of the foregoing’, such that the items following are merely examples of items which are included and/or items which are identified as being included for the avoidance of any doubt as to their inclusion, and such items are not descriptive of the class of items which may be included. |
| 1.12 | The headings in this Agreement are for ease of reference only and shall not affect its interpretation. |
| 2.1 | Leicester will start to perform the Project promptly after the commencement date of the Contract Period and will use its reasonable endeavours to perform the Project substantially in accordance with Annex 1. The Sponsor acknowledges that the Project is research based and experimental in nature and as such, specific results cannot be guaranteed. |
| 3.1 | Leicester will submit a final report to the Sponsor within three (3) months of:- |
| 3.1.1 | the end of the Contract Period; or if earlier |
| 3.1.2 | the termination of this Agreement. |
| 3.2 | During the term of this Agreement, representatives of Leicester will meet or otherwise communicate with representatives of the Sponsor at agreed times and places to discuss the progress and Results, ongoing plans and proposed changes in the Project. In addition to the Costs, the Sponsor will pay travel costs reasonably incurred by Principal Investigators or other Leicester representatives as may be required to attend such meetings with representatives of the Sponsor. |
| 4 | Costs, Billings and other Support |
| 4.1 | Leicester will invoice the Sponsor, in pounds Sterling, quarterly in advance, for the costs outlined in Annex 2, except that any costs incurred under Clause 3.2 will be paid in arrears. |
| 4.2 | The Costs will be paid by the Sponsor within 30 days of the date of Leicester’s invoice. The Sponsor will also pay VAT at the prevailing rate, if applicable. |
| 4.3 | If the Sponsor fails to pay any Costs on the due date, Leicester may, without prejudice to its other rights and remedies, charge the Sponsor interest in respect of the sum overdue in accordance with The Late Payment of Commercial Debts (Interest) Act 1998 from the due date for payment to the date of actual payment (both dates inclusive) and Leicester will be entitled to reimbursement of all expenses (including legal fees) incurred with respect to collection of overdue Costs. |
| 4.4 | The Sponsor shall provide support and contribute to the Project as set out in Annex 1. |
Leicester shall not be liable for any delay or non-performance of its obligations hereunder where such delay or non-performance is as a result of the Sponsor’s failure to provide its support or contribution including but not limited to the Costs.
| 5.1 | The Sponsor will not use the name of Leicester, nor of any member of Leicester’s Project staff, in any publicity, advertising or news release without the prior written approval of an authorised representative of Leicester. Other than for annual reporting purposes, Leicester will not use the name of the Sponsor, nor any employee of the Sponsor, in any publicity without the prior written approval of the Sponsor. Notwithstanding the foregoing, Sponsor may disclose any information, including the name of Leicester, required to be disclosed under applicable laws or regulations, including regulations of the United States Securities and Exchange Commission or any applicable stock exchange. |
| 6.1 | Each Party will not during the Agreement and for a period of three (3) years after the date of termination of this Agreement disclose the other Party’s Confidential Information. |
| 6.2 | Leicester will treat Arising IP and the Results as Confidential Information of the Sponsor and, except as set forth in Clause 8, shall obtain the prior written consent of the Sponsor before disclosing the same to any third party, such consent not to be unreasonably withheld or delayed. |
| 6.3 | The obligations in Clauses 6.1 and 6.2 shall not apply or shall cease to apply to Confidential Information which: |
| 6.3.1 | has been received from a third party who are not bound by an obligation of confidentiality to the Disclosing Party; |
| 6.3.2 | was already in the Receiving Party’s possession prior to its acquisition from the Disclosing Party as evidenced by written records; |
| 6.3.3 | was independently generated by the Receiving Party as evidenced by written records; |
| 6.3.4 | is in or comes into the public domain other than by reason of a breach of this Agreement; |
| 6.3.5 | is required to be disclosed by law or a court or other competent authority including, but not limited to, disclosures required under the Freedom of Information Act 2000, the Freedom of Information (Scotland) Act 2002 and the Environmental Information Regulations 2004; or |
| 6.3.6 | is disclosed with prior written consent of the Disclosing Party. |
| 7 | Anti-Corruption and Bribery Act |
| 7.1.1 | shall comply with all applicable laws, statutes, regulations relating to anti-bribery and anti-corruption including, but not limited to, the Bribery Act 2010 and not engage in any activity, practice or conduct which would constitute an offence under the Bribery Act 2010 if such activity, practice or conduct had been carried out in the UK; |
| 7.1.2 | warrants and represents (without limiting the generality of 7.1.1) to the other that it has not offered to give or agreed to give to any person any gift or consideration of any kind as an inducement or reward for doing or forbearing to do or for having done or forborne to do any act in relation to the obtaining or execution of this Agreement or for showing or forbearing to show favour or disfavour to any person in relation to this Agreement; |
| 7.1.3 | shall procure that any person who is performing services or providing goods in connection with this Agreement abides by the terms of this Agreement. |
| 7.2.1 | promptly report to Leicester any request or demand which if complied with would amount to a breach of either this Agreement or the Bribery Act 2010. |
| 7.3 | The obligations of the Parties under this Agreement impose no further obligation on either Party: |
| 7.3.1 | to prescribe, provide favourable status for, or otherwise support the other Party’s or a third party’s products or services; or |
| 7.3.2 | to supply services or to provide anything other than that which is set out in this Agreement. |
| 7.4 | Breach of this Clause 7 shall be deemed a material breach of this Agreement. |
| 8.1 | The Sponsor recognises that Leicester staff will normally wish to publish the Results and/or Arising IP. Leicester will: |
| 8.1.1 | provide to Sponsor a draft of any proposed paper or article at least 30 days prior to its submission for publication; and |
| 8.1.2 | provide a draft of any proposed oral presentation to the Sponsor at least 30 days prior to the date of the oral presentation; and |
| 8.1.3 | acknowledge all contributors to the Results and/or Arising IP within the paper, article and/or presentation. |
| 8.2 | Within 30 days of the date of provision to the Sponsor under Clause 8.1, the Sponsor may in writing:- |
| 8.2.1 | notify Leicester of its approval; or |
| 8.2.2 | request reasonable amendments to protect the Sponsor’s commercial interests; and/or |
| 8.2.3 | request a reasonable delay to publication (limited to a maximum of 30 days from the date of receipt of the Sponsor’s response) to the extent required to file patent applications in such Arising IP. |
| 8.3 | If Leicester receives no notification under Clause 8.2 within 30 days of the date of provision to the Sponsor, the Sponsor will be deemed to have given approval. Leicester will comply with any reasonable requests provided timely pursuant to Clause 8.2. |
| 8.4 | The Sponsor will not publish the Results and/or Arising IP without the prior written consent of Leicester, such consent at Leicester’s sole discretion but not to be unreasonably withheld. |
| 9.1 | All Background IP used in connection with the Project shall remain the property of the Party to whom it belonged prior to the commencement of the Project. For the avoidance of doubt, any IP licenced to AmpliPhi under the Licence Agreement shall remain subject to the Licence Agreement. |
| 9.2 | All rights to Arising IP under the Project shall belong in the first instance to the Sponsor. Leicester hereby assigns to Sponsor all right, title and interest to any Arising IP. |
| 9.3 | The Sponsor may, at its sole cost, apply for patent or other IP protection in the Sponsor’s name for any Arising IP. Leicester will cooperate with the Sponsor in executing such documents as may be reasonably required in the prosecution of such application(s). |
| 9.4 | The Sponsor will pay all reasonable costs incurred by Leicester for any assistance that Leicester provides to the Sponsor in respect of Clause 9.3 and/or in support of any application for patent or other IP protection. |
| 9.5 | The Sponsor will not allow to lapse its rights to apply for protection of or prosecution or maintenance of the protection of the Arising IP without first notifying Leicester in writing of its intention not to apply for protection of, or prosecution or maintenance of the protection of, the Arising IP and without offering rights to the Arising IP and rights to protect, prosecute and maintain the protection of the Arising IP to Leicester free of charge. Leicester will then be free to file or continue prosecution or maintain any such application(s) and to maintain any protection in any jurisdiction at Leicester’s sole expense. |
| 9.6 | The Sponsor will grant to Leicester a perpetual, non-exclusive, sub-licensable, royalty free licence to use the Arising IP and the Results for academic research and teaching purposes. |
| 10.1 | The Sponsor grants to Leicester a non-exclusive, sub-licensable, royalty-free licence to use the Arising IP and Results to the extent necessary for the purposes of the Project. |
| 10.2 | The Parties grant to each other a royalty-free right to use each other’s Background IP to the extent required for the purpose of the Project (during the Contract Period only) and subject to any third party rights to such Background IP. |
| 10.3 | If the Sponsor requires access to Background IP owned by Leicester (that is not already licenced to Sponsor under the Licence Agreement), Leicester expresses its willingness to grant a separate non-exclusive licence: |
| 10.3.1 | only to the extent required to commercialise the Results and/or Arising IP; |
| 10.3.2 | upon fair and reasonable commercial terms to be agreed; and |
| 10.3.3 | subject to any third party rights to such Background IP. |
| 11.1 | This Agreement will continue until the end of the Contract Period unless terminated in accordance with this Clause 11 or by mutual written agreement of the Parties. |
| 11.2 | Either Party may terminate this Agreement on written notice forthwith, if: |
| 11.2.1 | the other Party commits a material breach of this Agreement which has not been remedied after 90 days written notice of the breach (such notice expressly referring to possible termination of this Agreement); or |
| 11.2.2 | the Principal Investigator becomes unable or unwilling to continue the Project, and a mutually acceptable substitute is not available (such an event not to be treated as a breach of this Agreement). |
| 11.3 | Leicester may terminate this Agreement forthwith if the Sponsor enters into any arrangement or composition with its creditors, commits any act of bankruptcy or (being a corporation) if an order is made or an effective resolution is passed for its winding up (except for the purposes of amalgamation or reconstruction), or if a petition is presented to court, or if a receiver and manager, receiver, administrative receiver or administrator is appointed in respect of the whole, or any part of, the Sponsor’s undertaking or assets or there are reasonable grounds for anticipating the occurrence of any of these events within the foreseeable future. |
| 11.4 | Either Party may terminate this Agreement upon written notice to Leicester according to the following schedule: |
| Contract Year | | Cancellation Notice Period1 |
| November 13, 2015-November 12, 2016 | | 12 months |
| November 13, 2016-November 12, 2018 | | 6 months |
1Earliest date termination can take effect is November 13, 2016
| 11.5 | On termination of this Agreement (except for termination by the Sponsor under Clause 11.2.1) the Sponsor will pay all Costs falling due for payment prior to termination and any non-cancellable costs incurred after the date of termination arising from commitments reasonably incurred and/or entered into by Leicester in connection with the performance of the Project prior to the date of termination. |
| 11.6 | Subject to Clause 9, termination of the Agreement by either Party for any reason shall not affect the rights and obligations of the Parties accrued prior to the effective date of termination of this Agreement. No termination of this Agreement, for any reason, shall affect the Sponsor’s rights and duties under Clause 9. Those clauses of this Agreement which are expressly or impliedly intended to continue after termination shall continue in effect after termination. Clauses 4, 6, 9 and 10 will expressly continue after the termination of this Agreement. |
| 12.1 | In the performance of the Project under this Agreement Leicester shall be deemed to be and shall be an independent contractor and, as such, Leicester will not be entitled to any benefits applicable to employees of the Sponsor. |
| 12.2 | Neither Party is authorised or empowered to act as agent for the other for any purpose and shall not on behalf of the other enter into any contract, warranty, or representation as to any matter. Neither shall be bound by the acts or conduct of the other. |
| 13.1 | Notwithstanding any other provisions in this Agreement, nothing in this Agreement shall exclude or limit either Party’s liability for the following: |
| 13.1.1 | death or personal injury resulting from negligence; |
| 13.1.2 | fraud or statements made fraudulently; |
| 13.1.3 | any other acts or omissions for which the governing law prohibits the exclusion or limitation of liability. |
| 13.2 | Save as provided in Clause 13.1, Leicester will not be liable for any loss of profit, loss of business, loss of goodwill, loss of savings, claims by third parties, loss of anticipated savings, indirect loss or consequential loss whatsoever and howsoever caused including but limited to in relation to the supply of Materials (even if caused by Leicester’s negligence and/or breach of contract and even if Leicester was advised that such loss would probably result). |
| 13.3 | Subject to Clause 13.1 of this Agreement, Leicester’s total liability for any claims, losses, damages or expenses whatsoever and howsoever caused (even if caused by Leicester’s negligence and/or breach of contract) shall be limited for each event or series of linked events as follows: |
| 13.3.1 | in relation to liability arising out of a breach or negligence in connection with this Agreement to a maximum sum equal to the total Costs payable by the Sponsor to Leicester under the Agreement, or £400,000 whichever is the greater; |
| 13.3.2 | in relation to liability outside the scope of Clause 13.3.1, to £400,000. |
| 13.4 | Whilst Leicester will use all reasonable endeavours to ensure the accuracy of the work performed and any information and Results given, Leicester makes no warranty, express or implied, as to accuracy and, subject to Clause 13.1 will not be held responsible for any consequence arising out of any inaccuracies or omissions unless such inaccuracies or omissions are the result of Leicester’s negligence. |
| 13.5 | The Sponsor acknowledges that the nature of the Project is research based and the application of any Results will not be thoroughly tested. Accordingly, subject to Clause 13.1, Leicester will not be liable for any claims, losses, damages or expenses whatsoever and howsoever caused arising out of any use (or interpretation) by the Sponsor or any other party of the Results (or any product or process generated out of them), notwithstanding that the formulation of such product or process may be based upon the Results. |
| 14.1 | The Parties to this Agreement do not intend that any of its terms will be enforceable by virtue of the Contracts (Rights of Third Parties) Act 1999 by any person not a Party to it. |
| 15.1 | Each Party acknowledges that this Agreement and the Annexes contains the whole agreement between the Parties in respect of its subject matter and supersedes all prior arrangements agreements and understandings between them relating to the subject matter. It is acknowledged that the Annexes form part of this Agreement. For the avoidance of doubt, this Agreement is not intended to supersede the Licence agreement between the Parties dated 17th September 2013. |
| 16.1 | Any failure or delay by either Party in the performance of its obligations pursuant to this Agreement which is due to a force majeure event will not be deemed a default of this Agreement or a ground for termination. |
| 17.1 | This Agreement shall not be assigned by either Party without the prior written consent of the other, such consent not to be unreasonably withheld or delayed. Notwithstanding the foregoing, Sponsor may assign this Agreement in connection with any merger, consolidation or sale of all or substantially all of the assets of Sponsor to which this Agreement relates. |
| 18.1 | Any variation to this Agreement (and/or the Project) shall be in writing and signed by authorised signatories for both Parties. |
| 19.1 | If any provision of this Agreement is declared void or unenforceable, such provision shall be severed from this Agreement, which shall otherwise remain in full force and effect. |
| 20.1 | No failure, delay relaxation or indulgence on the part of either Party in exercising or partial exercise of any right hereunder shall operate as a waiver of such rights. |
| 21.1 | Any notice, demand or communication in connection with this Agreement will be in writing and may be delivered by hand, first class post, Special Delivery post but not by email addressed to the recipient below (or another person which the recipient has notified in writing to the sender in accordance with this Clause 21.1, to be received by the sender not less than seven days before the notice is despatched). |
| 21.1.1 | For Leicester — to Head of Commercial Contracts, Enterprise and Business Development Office, University of Leicester, University Road, Leicester, LE1 7RH, United Kingdom |
| 21.1.2 | For the Sponsor — M. Scott Salka, CEO, AmpliPhi Biosciences 3579 Valley Centre Drive, Suite 100, San Diego, CA 92130 with copies to: |
| 21.1.3 | Tom Coll, Cooley LLP, 4401 Eastgate Mall, San Diego, CA 92121 |
| 21.2 | The notice, demand or communication will be deemed to have been duly served: |
| 21.2.1 | if delivered by hand, at the time of delivery; |
| 21.2.2 | if delivered by first class post or Special Delivery post, 48 hours after being posted (excluding days other than business days in England). |
| 21.3 | The contacts for academic issues and day to day management of the Project will be: |
| 21.3.1 | For Leicester: - Dr Martha Clokie, Dept Infection, Immunity & Inflammation, University of Leicester, Maurice Shock Medical Sciences Building, University Road. Leicester, LE1 9HN, United Kingdom |
| 21.3.2 | For the Sponsor: - Dr, Sandra Morales, AmpliPhi Pty, Unit 7, 27 Dale Street, 2100 Brookvale, Australia, |
| 22.1 | All disputes will initially be referred by either Party to a representative of each Party responsible for the overall performance of this Agreement, who will meet as soon as reasonably practicable to discuss the dispute. If those representatives are unable to resolve the dispute after meeting, the dispute shall be referred to the Managing Director of the Sponsor and the Director of the Enterprise and Business Development Office of Leicester. The Directors will meet within 20 working days and attempt to resolve the dispute. |
| 22.2 | If any dispute arises out of this Agreement which the Directors are unable to resolve within 5 working days of their meeting pursuant to Clause 22.1, the Parties will attempt to settle it by mediation in accordance with the Centre for Dispute Resolution (CEDR) Model Mediation Procedure. |
| 22.3 | To initiate a mediation a Party must give notice in writing to the other Party requesting a mediation (the ‘ADR Notice’) and send a copy of the ADR Notice to CEDR. |
| 22.4 | If there is any point in the conduct of the mediation (including nomination of the mediator) upon which the Parties cannot agree within 14 days from the date of the ADR Notice, CEDR will, at the request of either Party, decide that point for the Parties, having consulted with them. |
| 22.5 | The mediation will start not later than 28 days after the date of the ADR Notice. |
| 22.6 | Neither Party may commence any court proceedings in relation to any dispute arising out of this Agreement until they have attempted to settle it by mediation and such attempt has been unsuccessful, provided that nothing in this Agreement will prevent either Party seeking injunctive relief to prevent or stay a breach of any provision of this Agreement. |
| 23.1 | This Agreement is governed by English law and the Parties submit to the exclusive jurisdiction of the courts of England and Wales. |
Annex 1
The Project
‘Development of Phage for the treatment of C. difficile infections’
Leicester’s contribution to the Project
Project program
Subject to the the Party’s mutual written agreement and ongoing approval, Leicester shall
perform the project broadly in accordance with the below:
Planned work
• Defining the actual mix. Have already identified the top 4 phage combinations that Leicester thinks is optimal. Leicester will validate this in vitro and in model systems in multiple strains.
• Establish if the mix can be improved by the substitution of new phages. PhD students in Leicester’s lab have independently isolated new C. difficile phages. Leicester will determine if these phage can improve the final mixture.
• Determine efficacy on biofilms. Use SEM/confocal /biofilm mass assays and enumeration of cfu’s of spores and vegetative cells to establish efficacy of phage treatment.
• Develop the Galleria mellonella model, to inform hamster work.
• Phage therapy as adjunct to antibiotic treatment (desired r/t essential). This would be carried out in vitro, and in model systems.
• Quantify variability within phages following propagation. Pick 32 plaques and determine variability using RFLPs/Sequence profiles.
• Develop PCR based assay to distinguish phages in ultimate mix. Multiplex if possible.
Ongoing work
• Viability at different pHs and temperatures (and to storage, 4 , -20 and -80°)
• Media development to meet GMP standards.
Work on modified phages
• Purify modified phages through several rounds of single plaque purification
• Establish production parameters for modified phages.
• Test spectrum of activity (host range) on clinical isolates compare data to original phages
• Sequence new phages and hosts
• Annotate genomes (to ascertain the new phages are devoid of integrases and non-desirable genes)
• Determine possible rates of resistance from phage treatments on clinical strains.
• Set up stability of phages on final mix
Dr Janet Nale will fulfil the role of Postdoctoral Research assistant for the project.
Sponsor’s contribution to the Project
In addition to funding the work, AmpliPhi will provide advice throughout the project through regular telecons, e-mails and meetings, AmpliPhi will provide modified phages and manufacturing hosts to Leicester as part of the collaboration. In the future (year 2 and beyond), manufacturing process development, analytical development and scale —up will take place at AmpliPhi.
Materials
Leicester and AmpliPhi may provide materials (including bacterial strains, phages, manufacturing hosts, DNA, etc.) to each other to be used in the Project. Any and all materials provided by the Parties under this Agreement shall be “Material” and subject to the following terms:
| a. | The transferred Materials are to be used only for the Project. |
| b. | The Parties shall not transfer each other’s Materials to any third party without the express written permission of the respective Party (with the exception that AmpliPhi can transfer Leicester materials to Intrexon as part of a research sublicense agreement provided that AmpliPhi shall ensure that Intrexon adhere to the terms and conditions contained herein and where applicable to the terms of the License Agreement). |
| c. | The transfer of all Materials must be agreed in advance in writing by an authorised representative of AmpliPhi, Professor Martha Clokie and the designated technology transfer representative of Leicester. For the purposes of this Clause, agreement by e-mail is acceptable. |
| d. | The transferred Materials shall remain the Background IP of the Party introducing such Materials. |
| e. | The Party receiving the Materials accepts and agrees that the Materials are experimental in nature, may have hazardous properties, and they are supplied on an ‘as is’ basis. The Party supplying the Materials makes no representation and gives no warranty or undertaking in relation to them whatsoever and excludes all implied warranties to the fullest extent permitted by law. |
| f. | In particular, the Party supplying the Materials makes no representations or warranties, express or implied (i) as to title, quality or fitness for a particular purpose or use of the Materials; (ii) that the supply by the supplying Party or the use by the receiving Party of the Materials will not infringe the IP rights of any third party; and (iii) in respect of third party rights that may be infringed by the manufacture, use, sale or transfer of, or with respect to title in, the Materials. |
| g. | The Party receiving the Materials warrants that, in relation to the Materials and their use they will comply with all relevant legislation and regulations. |
Annex 2
Financial
[…***…]
***Confidential Treatment Requested
| Signed | /s/ Wendy Johnson | | Signed | /s/ Dr. Katherine Hetherington |
| Authorised Signature for and on behalf of Sponsor | | Authorised Signature for and on behalf of Leicester |
| Name | Wendy Johnson | | Name | Dr. Katherine Hetherington |
| Position | Interim COO | | Position | Commercial Contracts Manager |
| Dated | Oct. 30, 2015 | | Dated | 4th November 2015 |
I have read and understood this Agreement
| Signed | /s/ Martha Clokie | |
| Name | Professor Martha Clokie | |
| Dated | 25/11/15 | |
